BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Week In Review | Apr 25, 2011
Clinical News

Micromet, Bayer preclinical data

In mouse xenograft models of prostate cancer, daily 0.05, 0.5 and 5 mg/kg IV MT112/BAY 2010112 significantly reduced mean tumor volume vs. vehicle-treated controls at day 16 (p<0.001 for all). Data were presented at the...
BC Week In Review | Nov 15, 2010
Company News

Micromet, Bayer deal

Micromet will receive a €2.5 million ($3.5 million) milestone payment from Bayer's Bayer Schering Pharma AG subsidiary under a 2009 deal in which Bayer exercised an option to co-develop and commercialize MT112 / BAY 2010112...
Items per page:
1 - 3 of 3